Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD33 CAR NK cells

A preparation of off-the-shelf natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the cluster of differentiation 33 (CD33) antigen, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD33 CAR NK cells target and bind to CD33 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells.
Synonym:allogeneic anti-CD33 chimeric antigen receptor-natural killer cells
Search NCI's Drug Dictionary